Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series

Catriona Harvey; Kazi J Nahar; Janet McKeown; Serigne N Lo; Sheima Farag; Nadia Yousaf; Kate Young; Liselotte Tas; Aafke Meerveld-Eggink; Christian Blank; Austin Thomas; Jennifer McQuade; Bastian Schilling; Douglas B Johnson; Roberto Martín Huertas; Ana Arance; Joanna Lee; Lisa Zimmer; Georgina V Long; Matteo S Carlino; Yinghong Wang; Alexander Maxwell Menzies

doi:10.1136/jitc-2023-008232

Article info

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series

Authors

Catriona Harvey Westmead Hospital WNH, Westmead, New South Wales, AustraliaMelanoma Institute Australia, North Sydney, New South Wales, Australia PubMed articles Google scholar articles
Kazi J Nahar Melanoma Institute Australia, North Sydney, New South Wales, AustraliaThe University of Sydney, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Janet McKeown Melanoma Institute Australia, North Sydney, New South Wales, AustraliaThe University of Sydney, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Serigne N Lo Research and Biostatistics Group, Melanoma Institute Australia, North Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Sheima Farag Royal Marsden Hospital NHS Trust, London, UK PubMed articles Google scholar articles
Nadia Yousaf Royal Marsden Hospital NHS Trust, London, UK PubMed articles Google scholar articles
Kate Young Royal Marsden Hospital NHS Trust, London, UK PubMed articles Google scholar articles
Liselotte Tas Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articles Google scholar articles
Aafke Meerveld-Eggink Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articles Google scholar articles
Christian Blank Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articles Google scholar articles
Austin Thomas The University of Texas Health Science Center at Houston, Houston, Texas, USA PubMed articles Google scholar articles
Jennifer McQuade University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Bastian Schilling Universitatsklinikum Wurzburg, Würzburg, Germany PubMed articles Google scholar articles
Douglas B Johnson Vanderbilt University Medical Center, Nashville, Tennessee, USA PubMed articles Google scholar articles
Roberto Martín Huertas Hospital Clinic de Barcelona, Barcelona, Spain PubMed articles Google scholar articles
Ana Arance Hospital Clinic and Institut D′Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain PubMed articles Google scholar articles
Joanna Lee The University of Sydney, Sydney, New South Wales, AustraliaWestmead Hospital, Westmead, New South Wales, Australia PubMed articles Google scholar articles
Lisa Zimmer Dermatology, University Hospital Essen, Essen, Germany PubMed articles Google scholar articles
Georgina V Long Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia PubMed articles Google scholar articles
Matteo S Carlino Westmead Hospital WNH, Westmead, New South Wales, Australia PubMed articles Google scholar articles
Yinghong Wang Gastroenterology, Hepatology & Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Alexander Maxwell Menzies Melanoma Institute Australia, North Sydney, New South Wales, AustraliaThe University of Sydney, Sydney, New South Wales, Australia PubMed articles Google scholar articles

Citation

Harvey C, Nahar KJ, McKeown J, et al

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series

Journal for ImmunoTherapy of Cancer 2024;12:e008232. doi: 10.1136/jitc-2023-008232

Online issue publication

January 31, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password